Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 41-57

  Tyebji, Shiraz ^a,b,c   Saavedra, Ana ^a,b,c   Canas, Paula M ^d,e   Pliassova, Anna ^d,e   Delgado García, José M ^f   Alberch, Jordi ^a,b,c   Cunha, Rodrigo A ^d,e   Gruart, Agnès ^f   Pérez Navarro, Esther ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Adenosine; CAMP; Dopamine; Hippocampus; PKA pathway; R6 1 mice; Rotarod; Striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE A2A RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; ROLIPRAM; 5-AMINO-7-(2-PHENYLETHYL)-2-(2-FURYL)PYRAZOLO(4,3-E)-1,2,4-TRIAZOLO(1,5-C)PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HIPPOCAMPUS; HUNTINGTON CHOREA; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CBA MOUSE; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BENZAZEPINES; COGNITION DISORDERS; CORPUS STRIATUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; HIPPOCAMPUS; HUNTINGTON DISEASE; LONG-TERM POTENTIATION; MALE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MOTOR ACTIVITY; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D1; TRIAZOLES;

EID: 84911934282     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.11.004     Document Type: Article

References (82)

1. Abel T., Nguyen P.V., Barad M., Deuel T., Kandel E.R., Bourtchouladze R. Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 1997, 88:615-626.
2. Andre V.M., Fisher Y.E., Levine M.S. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front. Syst. Neurosci. 2011, 5:46.
3. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 2002, 68:716-729.
4. Ariano M.A., Wagle N., Grissell A.E. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes. J. Neurosci. Res. 2005, 80:634-645.
5. Arnsten A.F., Ramos B.P., Birnbaum S.G., Taylor J.R. Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol. Med. 2005, 11:121-128.
6. Augusto E., Matos M., Sevigny J., El-Tayeb A., Bynoe M.S., Muller C.E., Cunha R.A., Chen J.F. Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J. Neurosci. 2013, 33:11390-11399.
7. Batalha V.L., Pego J.M., Fontinha B.M., Costenla A.R., Valadas J.S., Baqi Y., Radjainia H., Muller C.E., Sebastiao A.M., Lopes L.V. Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol. Psychiatry 2013, 18:320-331.
8. Bertran-Gonzalez J., Herve D., Girault J.A., Valjent E. What is the degree of segregation between striatonigral and striatopallidal projections?. Front. Neuroanat. 2010, 4.
9. Bliss T.V., Gardner-Medwin A.R. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaesthetized rabbit following stimulation of the perforant path. J. Physiol. 1973, 232:357-374.
10. Brandon E.P., Logue S.F., Adams M.R., Qi M., Sullivan S.P., Matsumoto A.M., Dorsa D.M., Wehner J.M., McKnight G.S., Idzerda R.L. Defective motor behavior and neural gene expression in RIIbeta-protein kinase A mutant mice. J. Neurosci. 1998, 18:3639-3649.
11. Canas P.M., Duarte J.M., Rodrigues R.J., Kofalvi A., Cunha R.A. Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiol. Aging 2009, 30:1877-1884.
12. Canas P.M., Simoes A.P., Rodrigues R.J., Cunha R.A. Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer's disease. Neuropharmacology 2014, 76(Pt A):51-56.
13. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:981-989.
14. Chagniel L., Bergeron Y., Bureau G., Massicotte G., Cyr M. Regulation of tyrosine phosphatase STEP61 by protein kinase A during motor skill learning in mice. PLoS One 2014, 9:e86988.
15. Charalambous C., Gsandtner I., Keuerleber S., Milan-Lobo L., Kudlacek O., Freissmuth M., Zezula J. Restricted collision coupling of the A2A receptor revisited: evidence for physical separation of two signaling cascades. J. Biol. Chem. 2008, 283:9276-9288.
16. Choi M.L., Begeti F., Oh J.H., Lee S.Y., O'Keeffe G.C., Clelland C.D., Tyers P., Cho Z.H., Kim Y.B., Barker R.A. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2014, 66:19-27.
17. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005, 93:310-320.
18. Cipriani S., Bizzoco E., Gianfriddo M., Melani A., Vannucchi M.G., Pedata F. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp. Neurol. 2008, 213:163-170.
19. Clarke J.R., Cammarota M., Gruart A., Izquierdo I., Delgado-Garcia J.M. Plastic modifications induced by object recognition memory processing. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2652-2657.
20. Costenla A.R., Diogenes M.J., Canas P.M., Rodrigues R.J., Nogueira C., Maroco J., Agostinho P.M., Ribeiro J.A., Cunha R.A., de Mendoça A. Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur. J. Neurosci. 2011, 34:12-21.
21. Costes S.V., Daelemans D., Cho E.H., Dobbin Z., Pavlakis G., Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 2004, 86:3993-4003.
22. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20(Suppl. 1):S95-S116.
23. del Toro D., Xifro X., Pol A., Humbert S., Saudou F., Canals J.M., Alberch J. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J. Neurochem. 2010, 115:153-167.
24. El-Ghundi M., Fletcher P.J., Drago J., Sibley D.R., O'Dowd B.F., George S.R. Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur. J. Pharmacol. 1999, 383:95-106.
25. Espinosa J., Rocha A., Nunes F., Costa M.S., Schein V., Kazlauckas V., Kalinine E., Souza D.O., Cunha R.A., Porciuncula L.O. Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. J. Alzheimers Dis. 2013, 34:509-518.
26. Ferrante A., Martire A., Pepponi R., Varani K., Vincenzi F., Ferraro L., Beggiato S., Tebano M.T., Popoli P. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease. Neurobiol. Dis. 2014, 7:193-204.
27. Fontinha B.M., Diogenes M.J., Ribeiro J.A., Sebastiao A.M. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 2008, 54:924-933.
28. Fontinha B.M., Delgado-Garcia J.M., Madronal N., Ribeiro J.A., Sebastiao A.M., Gruart A. Adenosine A(2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. Neuropsychopharmacology 2009, 34:1865-1874.
29. Fredholm B.B., Chen J.F., Cunha R.A., Svenningsson P., Vaugeois J.M. Adenosine and brain function. Int. Rev. Neurobiol. 2005, 63:191-270.
30. Gerlai R. Hippocampal LTP and memory in mouse strains: is there evidence for a causal relationship?. Hippocampus 2002, 12:657-666.
31. Gimenez-Llort L., Schiffmann S.N., Shmidt T., Canela L., Camon L., Wassholm M., Canals M., Terasmaa A., Fernandez-Teruel A., Tobena A., Popova E., Ferre S., Agnati L., Ciruela F., Martinez E., Scheel-Kruger J., Lluis C., Franco R., Fuxe K., Bader M. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol. Learn. Mem. 2007, 87:42-56.
32. Giralt A., Rodrigo T., Martin E.D., Gonzalez J.R., Mila M., Cena V., Dierssen M., Canals J.M., Alberch J. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 2009, 158:1234-1250.
33. Giralt A., Saavedra A., Carreton O., Xifro X., Alberch J., Perez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 2011, 20:4232-4247.
34. Giralt A., Carreton O., Lao-Peregrin C., Martin E.D., Alberch J. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener. 2011, 6:71.
35. Giralt A., Saavedra A., Alberch J., Perez-Navarro E. Cognitive dysfunction in Huntington's disease: humans, mouse models and molecular mechanisms. Journal of Huntington's disease 2012, 1:155-173.
36. Giralt A., Puigdellivol M., Carreton O., Paoletti P., Valero J., Parra-Damas A., Saura C.A., Alberch J., Gines S. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum. Mol. Genet. 2012, 21:1203-1216.
37. Giralt A., Saavedra A., Carreton O., Arumi H., Tyebji S., Alberch J., Perez-Navarro E. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. Hippocampus 2013, 23:684-695.
38. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 2004, 114:1624-1634.
39. Gruart A., Munoz M.D., Delgado-Garcia J.M. Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J. Neurosci. 2006, 26:1077-1087.
40. Gureviciene I., Ikonen S., Gurevicius K., Sarkaki A., van Groen T., Pussinen R., Ylinen A., Tanila H. Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice. Neurobiol. Dis. 2004, 15:188-195.
41. Halldner L., Lozza G., Lindstrom K., Fredholm B.B. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur. J. Pharmacol. 2000, 406:345-354.
42. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog. Neurobiol. 1998, 56:507-540.
43. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 2002, 277:18091-18097.
44. Huang Y., Hu Z., Liu G., Zhou W., Zhang Y. Cytokines induced by long-term potentiation (LTP) recording: a potential explanation for the lack of correspondence between learning/memory performance and LTP. Neuroscience 2013, 231:432-443.
45. Kheirbek M.A., Britt J.P., Beeler J.A., Ishikawa Y., McGehee D.S., Zhuang X. Adenylyl cyclase type 5 contributes to corticostriatal plasticity and striatum-dependent learning. J. Neurosci. 2009, 29:12115-12124.
46. Lee C.F., Chern Y. Adenosine receptors and Huntington's disease. Int. Rev. Neurobiol. 2014, 119:195-232.
47. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 2004, 27:691-697.
48. Li S., Cullen W.K., Anwyl R., Rowan M.J. Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nat. Neurosci. 2003, 6:526-531.
49. Lopes L.V., Halldner L., Rebola N., Johansson B., Ledent C., Chen J.F., Fredholm B.B., Cunha R.A. Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice. Br. J. Pharmacol. 2004, 141:1006-1014.
50. Lu Y., Zhang M., Lim I.A., Hall D.D., Allen M., Medvedeva Y., McKnight G.S., Usachev Y.M., Hell J.W. AKAP150-anchored PKA activity is important for LTD during its induction phase. J. Physiol. 2008, 586:4155-4164.
51. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
52. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst. Rev. 2009, CD006456.
53. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 2000, 20:5115-5123.
54. Ortiz O., Delgado-Garcia J.M., Espadas I., Bahi A., Trullas R., Dreyer J.L., Gruart A., Moratalla R. Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J. Neurosci. 2010, 30:12288-12300.
55. Paoletti P., Vila I., Rife M., Lizcano J.M., Alberch J., Gines S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 2008, 28:10090-10101.
56. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 2007, 81:331-348.
57. Popoli P., Blum D., Domenici M.R., Burnouf S., Chern Y. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr. Pharm. Des. 2008, 14:1500-1511.
58. Potenza R.L., Tebano M.T., Martire A., Domenici M.R., Pepponi R., Armida M., Pezzola A., Minghetti L., Popoli P. Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal 2007, 3:333-338.
59. Reader T.A., Briere R., Gottberg E., Diop L., Grondin L. Specific [3H]SCH23390 binding to dopamine D1 receptors in cerebral cortex and neostriatum: evidence for heterogeneities in affinity states and cortical distribution. J. Neurochem. 1988, 50:451-463.
60. Rebola N., Lujan R., Cunha R.A., Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008, 57:121-134.
61. Rodrigues R.J., Canas P.M., Lopes L.V., Oliveira C.R., Cunha R.A. Modification of adenosine modulation of acetylcholine release in the hippocampus of aged rats. Neurobiol. Aging 2008, 29:1597-1601.
62. Roman F.S., Truchet B., Marchetti E., Chaillan F.A., Soumireu-Mourat B. Correlations between electrophysiological observations of synaptic plasticity modifications and behavioral performance in mammals. Prog. Neurobiol. 1999, 58:61-87.
63. Rue L., Alcala-Vida R., Lopez-Soop G., Creus-Muncunill J., Alberch J., Perez-Navarro E. Early down-regulation of PKCdelta as a pro-survival mechanism in Huntington's disease. Neruomol. Med. 2014, 16:25-37.
64. Saavedra A., Giralt A., Rue L., Xifro X., Xu J., Ortega Z., Lucas J.J., Lombroso P.J., Alberch J., Perez-Navarro E. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J. Neurosci. 2011, 31:8150-8162.
65. Saavedra A., Giralt A., Arumi H., Alberch J., Perez-Navarro E. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. PLoS One 2013, 8:e73664.
66. Scott L.J. Tetrabenazine: for chorea associated with Huntington's disease. CNS. Drugs 2011, 25:1073-1085.
67. Spektor B.S., Miller D.W., Hollingsworth Z.R., Kaneko Y.A., Solano M., Johnson J.M., Penney J.B., Young A.B., Luthi-Carter R. Differential D 1 and D 2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res. Mol. Brain Res. 2002, 102:118-128.
68. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., Hannan A.J. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 2004, 24:2270-2276.
69. Takahashi R.N., Pamplona F.A., Prediger R.D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 2008, 13:2614-2632.
70. Tang T.S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
71. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., Abbracchio M.P. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 2006, 23:44-53.
72. The Huntington's Disease Collaborative Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
73. Torres-Peraza J.F., Giralt A., Garcia-Martinez J.M., Pedrosa E., Canals J.M., Alberch J. Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol. Dis. 2008, 29:409-421.
74. Trushina E., Singh R.D., Dyer R.B., Cao S., Shah V.H., Parton R.G., Pagano R.E., McMurray C.T. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 2006, 15:3578-3591.
75. Usdin M.T., Shelbourne P.F., Myers R.M., Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 1999, 8:839-846.
76. Varani K., Rigamonti D., Sipione S., Camurri A., Borea P.A., Cattabeni F., Abbracchio M.P., Cattaneo E. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 2001, 15:1245-1247.
77. Varani K., Abbracchio M.P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Cattabeni F., Borea P.A., Squitieri F., Cattaneo E. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 2003, 17:2148-2150.
78. Varani K., Bachoud-Levi A.C., Mariotti C., Tarditi A., Abbracchio M.P., Gasperi V., Borea P.A., Dolbeau G., Gellera C., Solari A., Rosser A., Naji J., Handley O., Maccarrone M., Peschanski M., DiDonato S., Cattaneo E. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiol. Dis. 2007, 27:36-43.
79. Villar-Menendez I., Blanch M., Tyebji S., Pereira-Veiga T., Albasanz J.L., Martin M., Ferrer I., Perez-Navarro E., Barrachina M. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neruomol. Med. 2013, 15:295-309.
80. 2A receptors in forebrain. Biol. Psychiatry 2014, 75:855-863.
81. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., Joyner A.L., MacDonald M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
82. Zucker R.S., Regehr W.G. Short-term synaptic plasticity. Annu. Rev. Physiol. 2002, 64:355-405.